Assessment of C-Reactive Protein and Markers of Oxidative Stress in Patients with Chronic Kidney Disease

Abstract

Chronic kidney failure (CKF) results from progressive loss of kidney function over a period of time. It is characterized by low glomerular filtration rate and the associated metabolic problems consequently haemodialysis is the mainstay of management of these patients prior to kidney transplant. CKF is associated with enhanced oxidative stress but scarce reports exist on the status of oxidative stress in these patients before haemodialysis. This therefore, formed the basis of this research. Fifty newly diagnosed non-dialyzed chronic kidney failure patients and thirty age and sex-marched healthy individuals participated in this study. Plasma sample was used to determine total antioxidant potential (TAP), total plasma peroxides (TPP) and urinary albumin, creatinine by standard spectrophotometric methods while oxidative stress index (OSI) was a ratio of TAP and TPP. CRP was quantified by single radial immunodiffusion method. Mid stream urine samples were assayed the same day for urinary albumin and creatinine. Statistical analysis was performed using two-tail student\'s t-test. Correlations between analytes were investigated using Pearson correlation co-efficient. All data were considered significant at p < 0.05. Significant increases were observed in the levels of total antioxidant potential (TAP) urinary albumin, urinary albumin / creatinine ratio in CKF patients compared with the controls. The urinary creatinine among CKF patients was significantly lower. Positive correlations was found between OSI and CRP. Significantly high level of TAP in undialyzed CKF patients ameliorates the oxidative effects of TPP.

Keywords

• -

Assessment of C-Reactive Protein and Markers of Oxidative Stress in Patients with Chronic Kidney Disease

Öz

-

Anahtar Kelimeler

• -

Kaynakça

1. Arias, E, Anderson RN, Kung HC, Murphy SL, Kochanek KP, Deaths: final data for 2001. National Vital Statitics Reports 2003; 52:1-115.
2. Quereshi AR, Alvestrannd A, Divino-Filho JC, et al. Inflammation, malnutrion and cardiac disease as pre- dictors of mortality in hemodialysis patients. J Am Soc Nephrol 2002;13:528-36.
3. Alebiosu CO, Ayodele OO, Abbas A, Olutoyin AI. Chronic renal failure at the Olabisi Onabanjo university teaching hospital, Sagamu, Nigeria. Afr Health Sci 2006;6(3):132–8.
4. Arora, P. and Verrelli, M, ‘Chronic Renal Failure’,Wikipedia, the free encyclopedia (2010).
5. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classi- fication, and stratification. Am J Kidney Dis 2002;39:S1– 266.
6. Ogun SA, Adelowo OO, Familoni OB, Jaiyesimi AEA, Fakoya EAO. Pattern and outcome of medical admissions at the Ogun State University Teaching Hospital Sagamu-a three years review. WAJM 2000;19(4):304–8.
7. Ceballos-Picot I, Witko-Sarsat V, Merad-Boudia M, Nguyen AT, Thevenin M, Jaudon MC, Zingraff J, Verger C, Jungers P, Descamps-Latscha P. Glutathione antioxidant system as a marker of oxidative stress in chronic renal failure. Free Radical Biology and Medicine 1996;21:845-53.
8. Miyata T, Fu MX, Kurokawa K, vanYpersele de Strihou C, Thorpe SR, Baynes JW. Autoxidation products of both carbohydrates and lipids are increased in uremic plas- ma: is there oxidative stress in uremia? Kidney Int 1998; 54:1290-5.

9. Morena M, Cristol JP, Canaud B. Why haemolysis patients are in peroxidative state? What could be done to correct the pro/antioxidant imbalance. Blood Purification 2000; 18:191-9.
10. Dobashi K, Ghosh B, Orak JK, Singh I, Singh AK. Kidney ish- chmia-reperfusion: modulation of antioxidant defenses. Mol Cell Biochem 2000;205:1-11.
11. Klahr S. Oxygen radicals and renal diseases. Miner Electrolyte Metab 1997;23:140-3.
12. Mimic-Oka J, Simic T, Djukanovic L, Reljic Z, Davicevic Z. Alteration in plasma antioxidant capacity in various degrees of chronic renal failure. Clin Nephrol 1999;51: 233–41.
13. Annuk M, Lind L, Linde T, Fellsto MB. Impaired endothe- lium dependent vasodilatation in renal failure in humans. Nephrol Dial Transplant 2001;16:302–6.
14. Tesch GH. Review: Serum and urine biomarkers of kidney disease: A pathophysiological perspective. Nephrology 2010;15:609–16.
15. Mark BP, Gideon MH. C-reactive protein: a critical update’ J Clin Investment 2003;15(111):1805-12.
16. Abraham G, Sundaram V, Mathew M, Leslie N, Sathiah V. C-Reactive protein, avaluable predictive marker in chronic kidney disease. Saudi J Kidney Dis Transplant 2009;20(5):811-5.
17. Zebrack JS, Anderson JL, Beddhu S. Do associations with C-reactive protein and extent of coronary artery disease account for the increased cardiovascular risk of renal in- sufficiency? J Am Coll Cardiol 2003;42:57-63.
18. Nguyen-Khoa T, Massy ZA, De Bandt JP, et al. Inflammation and duration of dialysis treatment. Nephrol Dialysis Transplant 2001;16:335-40.
19. Anderson MM, Requena JR, Crowley JR. The myeloper- oxidase system of human phagocytes generates Nepsilon- (carboxymethyl) lysine on proteins: a mechanism for pro- ducing advanced glycation end products at sites of inflam- mation. J Clin Invest 1999;104:103-13.
20. Stenvinkel P, Heimburger O, Paultre F, et al. Strong as- sociation between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 1999;55:1899–911.
21. Harma M, Harma M, Erel O. Increased oxidative stress in patients with hydatidiform mole’ Swiss Med Wkly 2003; 133:563-66.
22. Yeun JY, Levine RA, Mantadilok V. C-reactive protein pre- dicts all-cause and cardiovascular mortality in hemodialy- sis Patients. Am J Kidney Dis 2000;35:469-76.
23. Ortega O, Rodriguez I, Gallar P. Signiıficance of high C-reactive protein levels in predialysis patients. Nephrol Dial Transplant 2002;17;1105-9.
24. Galle J, Schnritder R, Heinloth A, ‘LP(a) and LDL induce apoptosis in human endothelial cells and in rabbit aorta: role of oxidative stress. Kidney Int 1999;55:1450-61.
25. Rule AD. Understanding estimated glomerular filtration rate: Implications for identifying chronic kidney disease. Curr Opin Nephrol Hypertens 2001;16:242–9.
26. Kusano C, Ferrari B. Total Antioxidant Capacity: a bio- marker in biomedical and nutritional studies. J Cell Mol Biol 2008;7(1):1-15.
27. Attman PO, Alaupovic P. Lipid and apolipoprotein profiles of uremic dyslipoproteinemia –relation to renal function and dialysis. Nephron 1995;57:401-10.
28. Oberg BP, McMenamin E, Lucas FL. Increased prevalence of oxidant stress and inflammation in patients with mod- erate to severe chronic kidney disease. Kidney Int 2004; 65:1009–116.
29. Glassock R. Debate: CON position. Should microalbumin- uria ever be considered as a renal endpoint in any clinical trial? Am J Nephrol 2010;31:462–5.
30. Jong P, Gansevoort RT. Albuminuria in non-primary renal disease: risk marker rather than risk factor. Nephrol Dial Transplant 2010;25:656–8.
31. Sofic E, Rustembegovic A, Kroyer G, Cao G. Serum antioxi- dant capacity in neurological, psychiatric, renal diseases and cardiomyopathy. J Neur Transm 2002;109:711-9.